THE DEAL, AT A GLANCE
From the announcementNuvation Bio
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedNuvation Bio raised $275M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersNuvation Bio is using Series B capital to advance AI-designed precision oncology therapeutics, with NUV-422 positioned around glioblastoma and a cofactor targeting…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Nuvation Bio · Financing Record
Explore source-linked visual explanations for Nuvation Bio. Unsupported claims are withheld while source review continues.
Record 454 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →